Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 360 participants.

Also called NCT04160000

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 360 participants (planned count) (from the registry)
Sponsor
Electrophysiology Research Foundation (from the registry)
Registry
  • NCT NCT04160000
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Germany, Switzerland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04160000. Randomized; no masking; primary purpose treatment. Start 2020-07-26 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Acronym
TAP-CHF
Condition
Heart Failure
Condition
Diastolic Heart Failure
Intervention (Device)
Catheter ablation
Intervention (Drug)
Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation
Intervention (Device)
Insertion of CardioMems Hemodynamic monitor
Intervention (Drug)
Empiric heart failure drug therapy
Lead sponsor
Electrophysiology Research Foundation (class: other)

Record details

Record id
cardio:ct-nct04160000
Content hash
085476d4ce5204ee0233a93e81d590aed9ad5056182346c31d63272f883c66ee